Supplementary Figures 1-4, Tables 1-2 from Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Figure 1. XPO1-KRAS synthetic lethal interaction identified using the Slorth database. Supplementary Figure 2. KRAS WT, KRAS G12D and KRAS G12V MEF cell lines were refractory to growth inhibition by selinexor or MRTX1257 or their combinations. Supplementary Figure 3. KRAS G12D mutant PDAC cell line Panc-1 was refractory to growth inhibition by KRAS G12C inhibitor AMG510. Supplementary Figure 4. Body weights of mice xenografted with MiaPaCa2 tumors were measured during the treatment period. Supplementary Table 1. Sequences of primers used. Supplementary Table 2. Combination Index (CI) values at various dose combinations of the drugs tested on different KRAS G12C mutant cell lines.
Authors: Husain Yar Khan, Misako Nagasaka, Yiwei Li, Amro Aboukameel, Md. Hafiz Uddin, Rachel Sexton, Sahar Bannoura, Yousef Mzannar, Mohammed Najeeb Al-Hallak, Steve Kim, Rafic Beydoun, Yosef Landesman, Hirva Mamdani, Dipesh Uprety, Philip A. Philip, Ramzi M. Mohammad, Anthony F. Shields, Asfar S. Azmi
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4362620604